Theyre being marketed asand, truly, you know, prescribed, tooas a lifelong treatment
They may reduce: Cardiovascular issues Sleep apnea and other breathing problems High blood pressure Alcohol depedency Kidney and liver disease Some types of cancer Of course, although both Ozempic and Wegovy are semaglutides, its important to note that they themselves are already approved for separate conditions
Concern isnt the right word
Additional studies are anticipated to provide more clarity on the long-term safety profile of Ozempic and related medications
Eur J Endocrinol 184(3):383394
March 2024 : The US FDA approved a label expansion for WEGOVY based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults with either overweight or obesity and established CVD